SG3 Management’s Blueprint Medicines BPMC Stock Holding History

SG3 Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25,000	Closed	-$1.6M	–	462
2022 Q1	$1.6M	Buy	+25,000	New	+$1.79M	0.04%	351
2021 Q4	–	Sell	-25,000	Closed	-$2.57M	–	1051
2021 Q3	$2.57M	Hold	25,000	–	–	0.08%	251
2021 Q2	$2.2M	Buy	+25,000	New	+$2.29M	0.08%	291

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

SG3 Management's BPMC Position: Q2 2022 in Review

SG3 Management sold out of Blueprint Medicines (BPMC) in Q2 2022, closing a stake of 18,500 shares — an estimated $1.18M sold.

SG3 Management first reported a position in BPMC in Q2 2021 and held it in 2 quarters. The position peaked at $1.18M in Q1 2022. 237 funds tracked by Wall St. Rank hold BPMC as of Q2 2022.

SG3 Management reported no remaining Blueprint Medicines position as of Q2 2022 after selling out during the quarter.
SG3 Management sold 18,500 Blueprint Medicines shares in Q2 2022, an estimated $1.18M.
SG3 Management first reported a position in Blueprint Medicines in Q2 2021 and held it in 2 quarters.
SG3 Management's Blueprint Medicines position peaked at $1.18M in Q1 2022.
237 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.